Brokerages predict that Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) will post ($0.86) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Ten analysts have issued estimates for Fate Therapeutics’ earnings. The lowest EPS estimate is ($1.00) and the highest is ($0.73). Fate Therapeutics reported earnings per share of ($0.58) during the same quarter last year, which would suggest a negative year-over-year growth rate of 48.3%. The business is scheduled to announce its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Fate Therapeutics will report full-year earnings of ($3.40) per share for the current financial year, with EPS estimates ranging from ($4.00) to ($2.91). For the next year, analysts expect that the business will report earnings of ($3.96) per share, with EPS estimates ranging from ($4.61) to ($3.07). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow Fate Therapeutics.
Fate Therapeutics (NASDAQ:FATE – Get Rating) last released its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.08. Fate Therapeutics had a negative return on equity of 34.89% and a negative net margin of 368.76%. The firm had revenue of $18.40 million during the quarter, compared to analysts’ expectations of $9.01 million. During the same period in the previous year, the firm posted ($0.48) EPS. Fate Therapeutics’s revenue for the quarter was up 65.2% on a year-over-year basis.
FATE opened at $22.64 on Tuesday. Fate Therapeutics has a 12 month low of $20.49 and a 12 month high of $97.43. The stock has a market capitalization of $2.19 billion, a price-to-earnings ratio of -9.32 and a beta of 1.69. The business has a fifty day moving average price of $34.26 and a 200 day moving average price of $43.06.
In other Fate Therapeutics news, insider Yu-Waye Chu sold 4,062 shares of the company’s stock in a transaction that occurred on Tuesday, April 19th. The stock was sold at an average price of $35.37, for a total transaction of $143,672.94. Following the completion of the sale, the insider now directly owns 151,033 shares of the company’s stock, valued at approximately $5,342,037.21. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO J Scott Wolchko sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, April 21st. The shares were sold at an average price of $35.00, for a total value of $1,050,000.00. Following the sale, the chief executive officer now directly owns 431,546 shares of the company’s stock, valued at $15,104,110. The disclosure for this sale can be found here. Insiders sold a total of 90,624 shares of company stock valued at $3,270,224 over the last three months. Company insiders own 18.58% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of FATE. Eaton Vance Management raised its stake in Fate Therapeutics by 99.6% during the 3rd quarter. Eaton Vance Management now owns 545 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 272 shares during the last quarter. Lindbrook Capital LLC raised its stake in Fate Therapeutics by 1,444.4% during the 4th quarter. Lindbrook Capital LLC now owns 556 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 520 shares during the last quarter. Concord Wealth Partners raised its stake in Fate Therapeutics by 939.8% during the 4th quarter. Concord Wealth Partners now owns 915 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 827 shares during the last quarter. Compagnie Lombard Odier SCmA purchased a new stake in Fate Therapeutics during the 1st quarter valued at approximately $70,000. Finally, Canada Pension Plan Investment Board raised its stake in Fate Therapeutics by 575.9% during the 4th quarter. Canada Pension Plan Investment Board now owns 1,994 shares of the biopharmaceutical company’s stock valued at $117,000 after acquiring an additional 1,699 shares during the last quarter.
Fate Therapeutics Company Profile (Get Rating)
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors.
- Get a free copy of the StockNews.com research report on Fate Therapeutics (FATE)
- FIGS, Inc Moves Lower On Analysts’ Downgrades
- MarketBeat Podcast: Trading Volatile Markets While Preserving Capital
- Option Care Health Stock is Making a Healthy Pullback
- Warby Parker Stock Is A High-Probability Candidate For A Short-Squeeze
- Concentrix: High Debt and Struggling Margins
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.